Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial-Reference-Cited by-同舟云学术

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Published:2024-09-14 Issue: Volume: Page:
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Khoury Katia^ORCID,Meisel Jane L.,Yau Christina,Rugo Hope S.^ORCID,Nanda Rita^ORCID,Davidian Marie,Tsiatis Butch,Chien A. Jo,Wallace Anne M.,Arora Mili,Rozenblit Mariya,Hershman Dawn L.,Zimmer Alexandra^ORCID,Clark Amy S.,Beckwith Heather,Elias Anthony D.,Stringer-Reasor Erica,Boughey Judy C.^ORCID,Nangia Chaitali,Vaklavas Christos^ORCID,Omene Coral,Albain Kathy S.,Kalinsky Kevin M.^ORCID,Isaacs Claudine^ORCID,Tseng Jennifer,Roussos Torres Evanthia T.^ORCID,Thomas Brittani,Thomas Alexandra^ORCID,Sanford Amy,Balassanian Ronald,Ewing Cheryl,Yeung Kay,Sauder Candice^ORCID,Sanft Tara,Pusztai Lajos^ORCID,Trivedi Meghna S.,Outhaythip Ashton,Li Wen,Onishi Natsuko^ORCID,Asare Adam L.,Beineke Philip,Norwood Peter,Brown-Swigart Lamorna^ORCID,Hirst Gillian L.^ORCID,Matthews Jeffrey B.,Moore Brian,Fraser Symmans W.,Price Elissa,Beedle Carolyn,Perlmutter Jane,Pohlmann Paula^ORCID,Shatsky Rebecca A.,DeMichele Angela^ORCID,Yee Douglas^ORCID,van ‘t Veer Laura J.^ORCID,Hylton Nola M.,Esserman Laura J.^ORCID

Funder

U.S. Department of Health & Human Services | National Institutes of Health

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41591-024-03266-2.pdf

Reference31 articles.

1. Nanda, R. et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer. JAMA Oncol. 6, 676–684 (2020).

2. Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810–821 (2020).

3. I-SPY2 Trial Consortium. Association of event-free and distant recurrence–free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer. JAMA Oncol. 6, 1355–1362 (2020).

4. Li, W. et al. Abstract P4-02-10: MRI models by response predictive subtype for predicting pathologic complete response. Cancer Res. 83, P4-02-10 (2023).

5. Wolf, D. M. et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell 40, 609–623.e6 (2022).